Evaluation of phage display system and leech-derived tryptase inhibitor as a tool for understanding the serine proteinase specificities

• Published in: Archives of biochemistry and biophysics Vol. 425; no. 1; pp. 87 - 94
• Main Authors: Campos, Ivan T.N, Silva, Melissa M, Azzolini, Simone S, Souza, Adriana F, Sampaio, Claudio A.M, Fritz, Hans, Tanaka, Aparecida S
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2004
• Subjects: Animals; Combinatorial library; Enzyme Inhibitors - pharmacology; Fibrinolysin - antagonists & inhibitors; Filamentous phage; Humans; Kazal-type serine proteinase inhibitor; Leeches - metabolism; Leukocyte Elastase - antagonists & inhibitors; Mutation; Neutrophil elastase inhibitor; Peptide Library; Phage display system; Plasmin inhibitor; Proteins - genetics; Proteins - pharmacology; Serine Endopeptidases - drug effects; Tryptases; Kazal-type serine proteinase inhibitor; Filamentous phage; Neutrophil elastase inhibitor; Plasmin inhibitor; Phage display system; Combinatorial library
• ISSN: 0003-9861; 1096-0384
• DOI: 10.1016/j.abb.2004.03.004

A small combinatorial library of LDTI mutants (5.2 × 10 4) restricted to the P1–P4 ′ positions of the reactive site was displayed on the pCANTAB 5E phagemid, and LDTI fusion phages were produced and selected for potent neutrophil elastase and plasmin inhibitors. Strong fusion phage binders were analyzed by ELISA on enzyme-coated microtiter plates and the positive phages had their DNA sequenced. The LDTI variants: 29E (K8A, I9A, L10F, and K11F) and 19E (K8A, K11Q, and P12Y) for elastase and 2Pl (K11W and P12N), 8Pl (I9V, K11W, and P12E), and 10Pl (I9T, K11L, and P12L) for plasmin were produced with a Saccharomyces cerevisiae expression system. New strong elastase and plasmin inhibitors were 29E and 2Pl, respectively. LDTI-29E was a potent and specific neutrophil elastase inhibitor ( K i=0.5 nM), affecting no other tested enzymes. LDTI-2Pl was the strongest plasmin inhibitor ( K i=1.7 nM) in the LDTI mutant library. This approach allowed selection of new specific serine proteinase inhibitors for neutrophil elastase and plasmin (a thrombin inhibitor variant was previously described), from a unique template molecule, LDTI, a Kazal type one domain inhibitor, by only 2–4 amino acid replacements. Our data validate this small LDTI combinatorial library as a tool to generate specific serine proteinase inhibitors suitable for drug design and enzyme-inhibitor interaction studies.